Vestmark Advisory Solutions’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Vestmark Advisory Solutions’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,476	Closed	-$282K	–	915
2022 Q4	$282K	Buy	+2,476	New	+$206K	0.01%	692
2022 Q3	–	Sell	-2,508	Closed	-$200K	–	891
2022 Q2	$200K	Buy	2,508 +287	+13%	+$27.2K	0.01%	815
2022 Q1	$234K	Buy	+2,221	New	+$216K	0.01%	797

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vestmark Advisory Solutions's HZNP Position: Q1 2023 in Review

Vestmark Advisory Solutions sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 2,476 shares — an estimated $282K sold.

Vestmark Advisory Solutions first reported a position in HZNP in Q1 2022 and held it in 3 quarters. The position peaked at $282K in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Vestmark Advisory Solutions reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Vestmark Advisory Solutions sold 2,476 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $282K.
Vestmark Advisory Solutions first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 3 quarters.
Vestmark Advisory Solutions's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $282K in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Vestmark Advisory Solutions's 13F filing for Q1 2023, filed 9 May 2023.